Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female subjects of childbearing potential must have a negative serum pregnancy within three days prior to registration for protocol therapy
Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential
Female patients who are pregnant; a pregnancy test is required for female patients of childbearing potential
Female patients who are pregnant are not eligible; Note: a pregnancy test is required for female patients of childbearing potential prior to study entry
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Patients who are pregnant; pregnancy test is required for female patients of childbearing potential
Patients who are pregnant; (a negative pregnancy test is required for female patients of childbearing potential)
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have a negative serum or urine pregnancy test
If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within  days of the first dose of study drug and must not be breast feeding
Female patients of childbearing potential must have a negative serum pregnancy test within  days prior to enrollment
Female subjects of childbearing potential must have a negative serum or urine pregnancy test within  days of initiating protocol therapy
Female patients who are pregnant or currently breastfeeding; female patients of childbearing potential must have a negative serum pregnancy test prior to enrollment
Female subjects of childbearing potential must have a negative serum or urine pregnancy test within  days of initiating protocol therapy
Female subjects of childbearing potential must have a negative serum pregnancy test at screening
Female subjects of childbearing potential must have a negative pregnancy test at screening
Female subjects of childbearing potential must have a negative serum pregnancy test at screening
Female patients must have a negative serum pregnancy test or be of non-childbearing potential.
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients who have menstruated and are of childbearing potential must have a negative serum or urine pregnancy test within  days prior to registration
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated)
Negative serum pregnancy test within  days prior to the administration of the study drugs for female patients of childbearing potential.
Pregnancy (negative serum pregnancy test to be obtained within  days prior to enrollment for subjects of childbearing potential)
Female participants of childbearing potential are to have a negative serum pregnancy test
Female patients of childbearing potential must have a negative pregnancy test within  week prior to beginning study treatment.
Pregnant and/or breastfeeding; a negative serum or urine pregnancy test is required at screening for all female patients of childbearing potential
Female patients of childbearing potential must have a negative serum or urine pregnancy test within  days prior to initiating dosing. Male and female subjects with reproductive potential must agree to use acceptable contraceptive methods while on study therapy and for  week following their last dose of study medication.
Female patients of childbearing potential must have a negative serum pregnancy test at the time of enrollment
Has a negative serum pregnancy test within  days of first dose of study treatment (female patients of childbearing potential)
Female patients of childbearing potential must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test within  days of registration.
Female patients of childbearing potential must have a negative pregnancy test, as measured by serum or urine testing
Female subjects of childbearing potential must be nonpregnant, nonlactating, and have a negative pregnancy test result at Screening and Day  of Cycles -.
Within  days of enrollment and with  h of starting lymphodepleting chemotherapy: Negative serum pregnancy test (female subjects of childbearing potential).
For female subjects of childbearing potential, a negative serum pregnancy test.
For female subjects of childbearing potential, a negative urine or serum pregnancy test prior to the start of study therapy.
Female patients of childbearing potential must have a negative serum pregnancy test within  days prior to enrollment; male and female patients must use an effective contraceptive method during the study and for a minimum of  months after study treatment
Female participants of childbearing potential must have negative results for pregnancy test performed:
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test
Female subject of childbearing potential should have a negative pregnancy test within  days prior to receiving the first dose of study medication
Female subjects of childbearing age must have a negative serum pregnancy test at study entry
Female patients of childbearing potential must have a negative serum pregnancy test within  days prior to enrollment
Pregnant females are excluded; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of radiation therapy
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment
Patients of childbearing potential must have a negative pregnancy test within  days prior to treatment start to be eligible
Negative pregnancy test within  days of day  cycle  for female patients of childbearing potential.
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test within  days of registration
Female patients of childbearing potential, negative urine pregnancy test done =<  days prior to study registration
Female subjects of childbearing potential should have a negative serum pregnancy =<  days prior to registration
Female patients of childbearing potential must have a negative pregnancy test <  week prior to enrollment.
Female patients of childbearing potential who have a positive blood or urine pregnancy test at screening
Female patient of childbearing potential has a negative serum pregnancy test within  days of study enrollment
Female patients of childbearing potential must have a negative serum pregnancy test within  days
Have a negative pregnancy test if a female with childbearing potential
Female patients of childbearing potential must have a negative serum pregnancy test confirmed within  days prior to enrollment
Female participants of childbearing potential have a negative urine or serum pregnancy test and must be willing to use an adequate method of contraception
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment
Negative pregnancy test (urine or serum) for female patients of childbearing potential
Pregnant or lactating women; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to the initiation of radiation therapy
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).
Female patients of childbearing potential must have a negative pregnancy test within  days of radiation start
Negative pregnancy test in female patients of childbearing potential
Negative pregnancy test in female patients of childbearing potential
STEP : Negative pregnancy test in female patients of childbearing potential
Female patients of childbearing potential must have a negative pregnancy test within  weeks prior to entering this study
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen)
Female patients of childbearing potential must have a negative pregnancy test within  days of the start of treatment.
Female patients of childbearing potential must have a negative serum or urine pregnancy test
Negative pregnancy test of the blood within  days of starting treatment in female patient of childbearing potential
Female patients should be using highly effective contraceptive measures, and must have a negative pregnancy test prior to start of dosing if of childbearing potential
Pregnant or breast-feeding. Female patients of childbearing age must have negative serum or urine pregnancy test within  week of beginning therapy.
If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within  days of the first dose of study drug and must not be breast feeding
A negative pregnancy test (if female of childbearing potential).
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have a negative serum pregnancy test within  weeks prior to enrollment
Female patients of childbearing potential have positive urine or serum pregnancy test no more than  days prior to starting study drug.
Female patients of childbearing potential must have a negative pregnancy test within  weeks prior to enrollment, and
Female patients of childbearing potential must have a negative serum or urine pregnancy test
Female participants of childbearing potential must have a negative serum pregnancy test within the  days prior to the first study drug administration.
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test (within  days prior to study registration)
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Patients who are pregnant; a pregnancy test is required for female patients of childbearing potential
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential must have negative serum pregnancy test within  days of starting protocol therapy
Female patients of childbearing potential must have a negative pregnancy test
A negative pregnancy test in female patients of childbearing potential; women must not be breast-feeding
Female patients of childbearing potential must have a negative serum pregnancy test within  days of study entry
If female of childbearing potential, serum pregnancy test is negative
For female patients of childbearing potential, have a negative pregnancy test documented prior to randomization.
Negative serum pregnancy test if female and of childbearing potential
Any patients of childbearing potential must have a negative pregnancy test
Female participants of childbearing potential must have a negative serum pregnancy test within  days prior to first dose.
Female patients of childbearing potential must have negative urine pregnancy test no more than  days prior to starting study treatment
Pregnancy Status Female patients of childbearing potential, must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test.
Female participants must have a negative pregnancy test at screening if of childbearing potential or be of non-childbearing potential
Subject is of childbearing potential and does not have a negative pregnancy test.
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female patients of childbearing potential are not eligible unless a negative pregnancy text result has been obtained
Within  days of enrollment: If female of childbearing potential, urine pregnancy test is negative
Female subject of childbearing potential should have a negative pregnancy test or documentation of absence of pregnancy by a gynecologist within  weeks of initiating radiation therapy
Female patient of childbearing potential has a negative serum or urine pregnancy test within  days prior to administration of study therapy
Female patients who are pregnant or breastfeeding. Female patients of childbearing potential must have a negative pregnancy test and agree to use adequate contraception for the duration of the trial.
Female subject of childbearing potential should have a negative serum pregnancy within  weeks prior to starting radiation therapy or undergoing ablation
Pregnant or breast-feeding patients are excluded; female patients of childbearing potential must have a negative serum or urine pregnancy test at the time of enrollment; in addition, female patients of childbearing potential must have negative pregnancy tests within    days prior to starting pomalidomide (can use enrollment pregnancy test if within the - day limit) AND again within  hours prior to initiation of pomalidomide; this protocol defines the following childbearing potential risk categories as:\r\n* Female child/young adult of childbearing potential as a female who has:\r\n** Achieved menarche and/or breast development, in Tanner stage  or greater\r\n** Has not undergone a hysterectomy or bilateral oophorectomy, or has not been naturally postmenopausal for at least  consecutive months (i.e., has had menses at any time in the preceding  consecutive months)\r\n* Note: amenorrhea following cancer therapy does not rule out childbearing potential
Female subject of childbearing potential should have a negative serum pregnancy test
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test prior to the start of therapy (as clinically indicated)
Female patients of childbearing age must have negative pregnancy test
Female patients of childbearing potential must have a negative pregnancy test within  days of radiation start
For female participants of childbearing potential, a negative pregnancy test must be documented prior to enrollment.
If female of childbearing potential, negative pregnancy test
Female subjects of childbearing potential must not be pregnant or breast-feeding; female subjects of childbearing potential must have a negative serum or urine pregnancy test; (pregnancy test must be repeated within  hours prior to the start of therapy)
If a female of childbearing potential, had a negative serum pregnancy test within  days before enrollment, or within  hours before enrollment where required
Female patients of childbearing potential must have negative serum pregnancy test =<  days prior to starting study treatment
Female patients of childbearing potential must have a negative serum pregnancy test within  weeks prior to enrollment
Female patients of childbearing potential must have a negative pregnancy test at screening
If female of childbearing potential, pregnancy test is negative
Female subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.
Female patients of childbearing potential must have a negative serum pregnancy test within  days prior to enrollment
Female patients of childbearing potential (not postmenopausal for at least  months and not surgically sterile) must have a negative serum or urine pregnancy test within  days of study registration; pregnancy test must be repeated if performed >  days before starting study drug
Female subjects of childbearing potential, as defined in parent study, must have negative serum pregnancy tests at the time of transition to this study.
Pregnant females are excluded; female subjects of childbearing potential must indicate to their physician that there is not a possibility of being pregnant at the time of enrollment or have a negative pregnancy test prior to initiation of radiation therapy
Female patients of childbearing potential must have negative serum or urine pregnancy test; patient must not be pregnant or breast feeding
Female patient who is of childbearing potential must have a negative serum pregnancy test result within  weeks prior to starting study drugs.
Female subject of childbearing potential should have a negative serum pregnancy within  days prior to receiving the first dose of study medication
Female patients of childbearing potential must have a negative pregnancy test within  weeks prior to enrollment
Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within  week of beginning therapy
Female patients of childbearing potential must have a negative serum or urine pregnancy test, whichever is considered standard by the institution
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed within  weeks prior to enrollment.
If female of childbearing potential, participant presents with a negative blood pregnancy test
Female patients cannot be of childbearing age, or if they are, must have a negative pregnancy test prior to enrollment and be willing to use contraceptives during treatment and continue for  additional months
Female patient of childbearing potential has a negative pregnancy test within  days prior to the start of study drug.
Female patients who are not of childbearing potential, and female patients of childbearing potential who agree to use adequate contraceptive measures, who are not breastfeeding, and who have a negative serum pregnancy test within  hours prior to start of treatment.
Female subjects who are not of childbearing potential and fertile female subjects of childbearing potential who agree to use adequate contraceptive measures who are not breastfeeding, and who have a negative serum or urine pregnancy test within  hours prior to start of study treatment
Female patients of childbearing potential must have a negative serum or urine pregnancy test at the time of enrollment
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).
Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within  days of the first dose of study drug and must not be breast feeding.
Female subjects of childbearing age must have a negative serum pregnancy test at study entry
Female patients of childbearing potential must be non-pregnant, non-lactating, and have a negative pregnancy test result prior to enrollment in the study;
If female and of childbearing potential, documentation of negative pregnancy test (serum or urine) within  days prior to first dose
If the subject is a female of childbearing potential, has she had a negative serum pregnancy test within the past  days?
Female patients of childbearing potential must have a negative serum or urine pregnancy test result at time of pre-treatment screening.
Female patients of childbearing potential must have a negative serum pregnancy test
Female patients of childbearing potential must not be pregnant or breast-feeding; female patients of childbearing potential must have a negative serum or urine pregnancy test
Female patient of childbearing potential has a negative pregnancy test within  days prior to the start of study drug
If female and of childbearing potential, documentation of negative pregnancy test prior to enrollment.
Female participants of childbearing potential must have a negative serum pregnancy test
Female subject of childbearing potential must have a negative pregnancy test at screening
Pregnant or breast feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within  week of beginning therapy.
Female participants of childbearing potential must have a negative pregnancy test (urinary or serum beta-HCG).
Female patients of childbearing age must have a negative pregnancy test
Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained
Female subject of childbearing potential is neither pregnant nor lactating and must have a negative pregnancy test at the screen visit and a negative pregnancy test before dosing. All female subjects of childbearing potential and male subjects with female partners of childbearing potential must agree to use effective contraception (eg, implants, injectables, combined oral contraceptives, intrauterine device (IUD), sexual abstinence, vasectomy or vasectomized partner) for the duration of the study
Female subjects of childbearing potential must have a negative plasma pregnancy test upon study entry
Urine or serum pregnancy test: negative for female patients of childbearing potential
All female patients of childbearing potential including those who are within  year of last menstrual period will be required to take a pregnancy test during screening, enrollment and at week , ,  and 
Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen)
Pregnancy; female participants of childbearing potential must have documented negative urine or serum pregnancy test result not older than  days; male patients with reproductive potential will be counseled not to procreate during the study
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to starting study drug
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test
Female patients of childbearing potential must have a negative pregnancy test at screening
Female subjects of childbearing potential must have a negative pregnancy test
Female patients who are pregnant are not eligible; women of childbearing potential require a negative pregnancy test prior to enrollment
Individuals not pregnant at enrollment; female subjects of childbearing potential will undergo a pregnancy test prior to imaging
Individuals not pregnant at enrollment; female subjects of childbearing potential will undergo a pregnancy test prior to imaging
Subject is male; or is a female who is either surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (>  years without menses), >=  years old, or of childbearing potential for whom a pregnancy test (with the results known prior to investigational product administration) is negative; a negative pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is not capable of becoming pregnant; female must also be non-lactating
Negative serum or urine pregnancy test for female patients of childbearing age and potential (as defined by MSKCC Standards & Guidelines), from assays obtained <  weeks prior to study enrollment
Negative pregnancy test, to be performed on female patients of childbearing potential within  week before administration of radioactive material
Negative serum pregnancy test for female patients of childbearing age and potential (as defined by MSKCC standards & guidelines), from assays obtained <  weeks prior to study enrollment; patients will be advised against having unprotected sexual intercourse from the time of the negative serum pregnancy test until after completing their participation in the study
Subject is male; or is a female who is either pre-menarchal, surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (>  years without menses), non-lactating, or of childbearing potential for whom a serum pregnancy test (with the results known prior to investigational product administration) is negative; a negative serum pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is capable of becoming pregnant
Pregnant or breastfeeding (if a female is of childbearing potential, and unsure of pregnancy status, a standard pregnancy test should be done)
Negative serum pregnancy test (female of childbearing potential only)
Female patients of childbearing potential must have a negative serum or urine pregnancy test within  days of enrollment
Subject is male; or is a female who is either pre-menarchal, surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), postmenopausal (>  years without menses), non-lactating, or of childbearing potential for whom a serum pregnancy test (with the results known prior to investigational product administration) is negative; a negative serum pregnancy test will be required for all female subjects with child bearing potential; if a false pregnancy test is suspected, e.g., perimenopausal condition, an obstetrician will be consulted to determine if she is/is capable of becoming pregnant
Female subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within  days prior to start of study treatment)
Pregnancy (if a female is of childbearing potentialdefined as a premenopausal female capable of becoming pregnant-a pregnancy test should be done)
if female of childbearing potential must have a negative pregnancy test within  hours of enrollment
If female of childbearing potential, pregnancy test is negative; (in these instances, the patient will need to provide documentation of negative pregnancy test results)
Female subjects of childbearing potential must have a negative serum pregnancy test within  days prior to infusion
Criteria , Female subjects of childbearing potential should have a negative serum pregnancy test within  week prior to enrollment
Female subject of childbearing potential must have a negative pregnancy test within  hours prior to enrollment.
Female patients of childbearing potential must have a negative pregnancy test within  week prior to beginning study treatment.
